Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
AQUAPORIN Aktie jetzt für 0€ handeln | |||||
21.08. | Aquaporin A/S: Aquaporin announces results for first half 2025 | 305 | PR Newswire | Company announcement No. 16/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngby aquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug. 21, 2025 /PRNewswire/... ► Artikel lesen | |
13.08. | AQUAPORIN A/S: Aquaporin to host half-year 2025 results webcast on August 21 | 3 | Cision News | ||
12.08. | Aquaporin Cuts FY Revenue Guidance, Initiates Strategic Review | 1 | RTTNews | ||
11.08. | Aquaporin A/S: Aquaporin lowers revenue guidance for 2025, but maintains EBITDA guidance, and initiates strategic review | 1.051 | PR Newswire | Company announcementNo. 15/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug.... ► Artikel lesen | |
05.08. | Aquaporin A/S: Aquaporin successfully achieves up to 20% energy savings at Kranji NEWater Factory | 289 | PR Newswire | KONGENS LYNGBY, Denmark, Aug. 5, 2025 /PRNewswire/ -- Aquaporin has successfully completed the Living Lab Project to develop the world's first biomimetic low-energy Aquaporin Inside® CLEAR... ► Artikel lesen | |
08.07. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons discharging managerial responsibilities | 2 | Cision News | ||
07.07. | AQUAPORIN A/S: Aquaporin issues warrants under a new warrant program | 2 | Cision News | ||
20.06. | AQUAPORIN A/S: Major shareholder announcement | 2 | Cision News | ||
20.06. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons closely associated with persons discharging managerial responsibilities in Aquaporin | 2 | Cision News | ||
12.06. | Aquaporin A/S: Aquaporin appoints Chief Executive Officer | 400 | PR Newswire | Company announcementNo. 09/2025
Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark... ► Artikel lesen | |
21.05. | Aquaporin A/S: Aquaporin Q1 2025 Trading Statement - maintains full-year financial guidance for 2025 | 328 | PR Newswire | Company announcementNo. 08/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark , May 21, 2025 /PRNewswire/... ► Artikel lesen | |
15.05. | AQUAPORIN A/S: Aquaporin sells 500 CLEAR membranes to Chinese company CRZLO | 2 | Cision News | ||
08.05. | AQUAPORIN A/S: Aquaporin membranes to power projects in Chile and Mexico | 1 | Cision News | ||
01.05. | AQUAPORIN A/S: Aquaporin secures pilot plant contract for Trinity College Dublin at the IBF National Bioeconomy Campus | 5 | Cision News | ||
11.04. | Aquaporin A/S - Admittance to trading and official listing of new shares due to exercise of warrants | 183 | GlobeNewswire | The share capital of Aquaporin A/S has been increased. The admittance of trading and official listing of new shares will take effect as per 14 April 2025 in the ISIN below.
ISIN:
DK0061555109
Name:
Aquaporin
Volume... ► Artikel lesen | |
20.03. | Aquaporin A/S: Aquaporin announces full-year 2024 results | 581 | PR Newswire | Company announcementNo. 03/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, March 20, 2025 /PRNewswire/... ► Artikel lesen | |
20.03. | Aquaporin A/S: Aquaporin announces guidance for 2025 | 149 | GlobeNewswire (Europe) | Company announcement
No. 02/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, March 20, 2025 -... ► Artikel lesen | |
26.02. | Aquaporin A/S: Aquaporin improves EBIT and specifies revenue guidance for 2024 | 141 | GlobeNewswire (Europe) | Company announcement
No. 01/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, February 26, 2025... ► Artikel lesen | |
14.11.24 | Aquaporin A/S: Aquaporin Q3 2024 Trading Statement | 570 | GlobeNewswire (Europe) | Company announcement
No. 19/2024
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Copenhagen, Denmark, November 14, 2024 - Aquaporin A/S (ticker:... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 42,045 | -0,05 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
VENTYX BIOSCIENCES | 6,850 | +77,46 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
TANGO THERAPEUTICS | 8,040 | -7,16 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million Financing | BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
EVOTEC | 6,812 | +1,28 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
BIONTECH | 90,25 | -1,53 % | PRESSESPIEGEL/Unternehmen: LEG, DEUTSCHE BAHN, FLINK, BIONTECH/CUREVAC, NEURAXPHARM | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
LEG - Der Chef des zweitgrößten deutschen Vermieters LEG, Lars von Lackum... ► Artikel lesen | |
HARMONY BIOSCIENCES | 28,970 | +10,36 % | Harmony Biosciences reports Q3 revenue of $239M, raises FY25 revenue guidance | ||
RECURSION PHARMACEUTICALS | 5,810 | +1,13 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
NEUMORA THERAPEUTICS | 2,190 | +27,70 % | H.C. Wainwright maintains Buy rating on Neumora stock ahead of obesity drug data | ||
AVIDITY BIOSCIENCES | 47,410 | +1,17 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
JANUX THERAPEUTICS | 26,060 | -1,03 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
NANOBIOTIX | 17,600 | -8,14 % | Nanobiotix S.A.: NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer | Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 18,800 | -1,78 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
HEIDELBERG PHARMA | 3,130 | +7,56 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma erhält Fast-Track-Status von der US FDA für seinen führenden ADC-Kandidaten HDP-101 zur Behandlung des multiplen Myeloms | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma erhält Fast-Track-Status von der US FDA für seinen führenden ADC-Kandidaten HDP-101 zur Behandlung... ► Artikel lesen | |
BEAM THERAPEUTICS | 28,280 | +2,20 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
QUANTUM-SI | 2,290 | +4,81 % | Cathie Wood's ARK buys Genedx, sells Quantum-Si stock |